News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) to Outline Cost Cuts Next Week After Suspension of Iclusig Sales



11/1/2013 8:05:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An Ariad Pharmaceuticals spokesman says cost reduction plans will be outlined next week after the company said Thursday it is temporarily suspending sales of its only approved drug in the wake of concerns that it may cause blood clots. The Cambridge drug company said Thursday morning in a statement that the U.S. Food and Drug Administration on Wednesday afternoon made “a request” that it halt marketing and distribution of the drug, which was approved on under accelerated approval last December to treat certain kinds of chronic myeloid leukemia after other drugs have failed.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES